Oxelumab

DB16663InvestigationalProtein Based Therapies

Oxelumab is under investigation in clinical trial NCT00983658 (A Study of HuMAb OX40L in the Prevention of Allergen-induced Airway Obstruction in Adults With Mild Allergic Asthma).

Mechanism: Pharmacologically active on Tumor necrosis factor ligand superfamily member 4
Curator reviewed
Code names: HuMAb OX-40L · OX-40L · R-4930 · R-4930 HUMAB OX40L · RO-49-89991

Resolves to

Compound

UNII67GFR7JCMNCAS1186098-83-8

Targets

P23510TNFSF4

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Oxelumab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account